Study of Tissue and Molecular Analysis in Diagnosing and Treating Small-Bowel Diseases Including Celiac Disease
Led by Tampere University Hospital · Updated on 2026-04-29
300
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating small-bowel diseases, focusing on celiac disease and other conditions causing mucosal injury. This observational study aims to establish reliable histological reference values for the normal small-bowel mucosa, improve diagnostic accuracy, and develop advanced molecular profiles to evaluate disease progression and treatment responses. The study recognizes the current variability and error rates in histological evaluations and seeks to enhance diagnostic quality through modern techniques.
Participants are divided into three groups healthy controls undergoing gastroscopy with no celiac disease suspicion and negative antibodies, patients referred for primary celiac disease diagnostics requiring duodenal biopsy, and patients with refractory small-bowel mucosal injury unresponsive to a gluten-free diet. Duodenal biopsies are collected and analyzed using digital morphometry, AI-based image analysis, RNA sequencing, and intestinal organoid cultures. These processes occur at the research center under secure data handling.
During the study, participants undergo routine clinical assessments, including standard pathology reviews of their biopsies. Researchers measure villus-to-crypt ratios and perform transcriptomic analyses to understand molecular changes. Additional evaluations include AI-driven image analyses and organoid modeling throughout the study period. Data is stored securely for 15 years. The study may last until December 2035, with primary outcome measures assessed up to December 2025 and ongoing molecular analyses extending through the entire period.
CONDITIONS
Brief Title
Histomolecular Profiling in Small-Bowel Diseases
Research Team
J
Juha Taavela
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent obtained prior to procedure
For healthy controls: Negative celiac disease antibodies (anti-transglutaminase and/or anti-endomysium); no suspicion of celiac disease
For celiac disease diagnostics group: Referred for primary celiac disease diagnostics requiring duodenal biopsy
For refractory injury group: Confirmed small-bowel mucosal injury not responsive to a gluten-free diet
You will not qualify if you...
For healthy controls: Other small-bowel diseases causing mucosal injury, including Crohn's disease and small-bowel ulcers
Inability to provide written informed consent
Refusal to participate
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Single day
Participants undergo clinically indicated upper gastrointestinal endoscopy during which research biopsies are obtained for histological and molecular profiling.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 13 years
Research biopsy samples are analyzed using digital morphometry, RNA sequencing, and AI/machine-learning methods to study disease progression and treatment response over time.
No additional visits required for research purposes
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Phase 1 Study to Assess Safety and Tolerability of a Single Oral Dose of HB-2121 for Diagnosing Celiac Disease in Adults
Multicenter Study to Develop and Validate an AI System for Detecting Small Bowel Damage in Celiac Disease and Other Enteropathies
Sharing Anonymized MRI Data to Develop Computer Tools for Small Bowel Assessment in Crohns Disease
Armenian Nationwide Registry for Patients with Systemic Autoimmune and Autoinflammatory Diseases
Tracking Disease Progress and Treatment Effects
Studying Genetic and Biological Differences in Coeliac Disease and Dermatitis Herpetiformis to Improve Personalized Care
Study of Genes, Environment, Microbiome, and Metabolites in Infants at Risk for Celiac Disease
Improving Capsule Endoscopy Diagnosis Using Artificial Intelligence to Reduce Reading Time and Enhance Accuracy
Study of Omega-3 Supplements with Gluten-Free Diet for Adults Newly Diagnosed with Celiac Disease to Reduce Inflammation and Improve Gut Health
Phase II Study of ZED1227 to Treat Symptoms in Adults With Celiac Disease Not Improved by a Gluten-Free Diet
Sanford Study Screening Children for Type 1 Diabetes and Celiac Disease Risk During Routine Healthcare Visits
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Histological, immunohistochemical and mRNA gene expression responses in coeliac disease patients challenged with gluten using PAXgene fixed paraffin-embedded duodenal biopsies.